Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (LLY) announced the launch of a new citrate-free formulation of Taltz (ixekizumab) injection, approved by the FDA in May 2022. This formulation aims to reduce injection site pain by 86% compared to the original. Taltz is prescribed for moderate to severe plaque psoriasis and other autoimmune conditions. Over 130,000 patients have been treated with Taltz in the U.S. since its approval in 2016. The new formulation has shown consistent safety profiles, and existing patients will not require new prescriptions during the transition period.

Eli Lilly and Company (NYSE: LLY) has rescheduled its second-quarter 2022 financial results investor conference call to 10 a.m. Eastern time due to technical difficulties. Investors and the public can access a live webcast through Lilly's website, with a replay available afterward. The company emphasizes its commitment to advancing healthcare solutions and improving patient access to medicines globally.

Eli Lilly and Company (LLY) reported Q2 2022 revenue of $6.49 billion, a 4% decline year-over-year, primarily due to lower realized prices and Alimta's generic competition. Excluding these factors, core revenue grew 6%. Key growth products, including Trulicity and Verzenio, surged 20%, comprising 67% of total revenue. EPS fell 31% to $1.05 (reported) and 32% to $1.25 (non-GAAP). The company updated its 2022 EPS guidance to $6.96-$7.11 (reported) and $7.90-$8.05 (non-GAAP). Notable advancements included the U.S. launch of Mounjaro and FDA approvals for donanemab and pirtobrutinib.

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Aug. 4, 2022, at 9 a.m. Eastern time. The company will hold a conference call to discuss its financial performance, accessible via a live webcast on Lilly's website. This event reflects Lilly's ongoing commitment to transparency with its investors and stakeholders, providing details of its business performance and future outlook.

Investors can find further information on the upcoming call and access details through Lilly's investor relations site.

Eli Lilly (NYSE: LLY) announced a modified agreement with the U.S. government to provide an additional 150,000 doses of the monoclonal antibody bebtelovimab for approximately $275 million. This supply is expected to meet the demand until late August 2022. Bebtelovimab continues to neutralize known variants, including the Omicron variants BA.2.12.1 and BA.4/BA.5. The deal is projected to generate approximately $0.08 in EPS. An option for an additional 350,000 doses exists, exercisable by September 14, 2022.

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend of $0.98 per share for the third quarter of 2022. This dividend is payable on Sept. 9, 2022 to shareholders of record as of Aug. 15, 2022. Eli Lilly, known for its significant contributions to healthcare, continues to work on advancements in various medical fields, including diabetes, obesity, and Alzheimer's disease. The company emphasizes its commitment to innovative clinical trials and the accessibility of its medicines.

Eli Lilly and Incyte announced that the FDA has approved OLUMIANT (baricitinib) as the first systemic treatment for adults with severe alopecia areata. Available in 1 mg, 2 mg, and 4 mg doses, OLUMIANT has shown promising results in clinical trials, with 32-35% of patients achieving over 80% scalp coverage. The approval follows the BRAVE-AA1 and BRAVE-AA2 trials, involving 1,200 patients. While the treatment offers hope for patients, it comes with serious risks, including infections and cardiovascular events. Manufacturers are also working on patient access programs to help with costs.

Eli Lilly and Company (NYSE: LLY) announced positive one-year results from Phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. Eighty percent of responders maintained skin clearance (EASI-75) over the year, with effective dosing every two to four weeks. The treatment also provided lasting itch relief. Safety profiles remained consistent with earlier studies, and no new safety signals were reported. Lilly plans to submit a Biologics License Application (BLA) to the FDA in H2 2022, supporting lebrikizumab's potential as a first-line biologic.

Eli Lilly's Mounjaro (tirzepatide) has demonstrated superior efficacy in reducing fat mass and achieving glycemic targets in adults with type 2 diabetes compared to injectable semaglutide and placebo, as presented at the ADA's 82nd Scientific Sessions. In a 28-week study, Mounjaro participants lost an average of 11.2 kg in weight and 9.7 kg in fat mass, significantly more than those on semaglutide. Mounjaro also helped participants reach A1C targets quicker, achieving A1C <7% in 8 weeks. The drug is FDA-approved and utilizes a dual-action mechanism of GIP and GLP-1 receptor agonism.